Brief: Genetron Health Receives U.S. FDA Breakthrough Device Designation For Its Blood-Based Ngs Test For Early Detection Of Hepatocellular Carcinoma
30/09/2020 13:13
Sept 30 (Reuters) - Genetron Holdings Ltd GTH.O :
* GENETRON HEALTH RECEIVES U.S. FDA BREAKTHROUGH DEVICE
DESIGNATION FOR ITS BLOOD-BASED NGS TEST FOR EARLY DETECTION OF
HEPATOCELLULAR CARCINOMA
* GENETRON HOLDINGS - EXPECTS TO ANNOUNCE FULL DATA SET FOR
STUDY
FROM ALL 2,000 PATIENTS IN FIRST HALF OF 2021
Source text for Eikon: ID:nGNX6XSkVl
Further company coverage: GTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genetron Holdings
See all newsBrief: Genetron Holdings Requested That Trading Of Its ADSs On Nasdaq Be Suspended As Of Close Of Trading On March 28, 2024
U.S. STOCKS ON THE MOVE-Cerevel Therapeutics, Scholar Rock, Helius
U.S. STOCKS ON THE MOVE-Scholar Rock, Target, LL Flooring
U.S. STOCKS ON THE MOVE-First Solar, Genetron, Viasat
Genetron surges on $126 mln deal to go private